{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=3",
    "query": {
      "condition": "Neovascularization, Pathologic",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 197,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T22:57:45.373Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01414153",
      "title": "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "4.0 mg iSONEP",
          "type": "DRUG"
        },
        {
          "name": "0.5 mg iSONEP",
          "type": "DRUG"
        },
        {
          "name": "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea",
          "type": "DRUG"
        },
        {
          "name": "sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2012-08",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 44,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01414153"
    },
    {
      "nct_id": "NCT01024998",
      "title": "Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Age-Related Maculopathies",
        "Age-Related Maculopathy",
        "Maculopathies, Age-Related",
        "Maculopathy, Age-Related",
        "Retinal Degeneration",
        "Retinal Neovascularization",
        "Gene Therapy",
        "Therapy, Gene",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "AAV2-sFLT01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-01-11",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Slingerlands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024998"
    },
    {
      "nct_id": "NCT00363168",
      "title": "Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2006-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2012-10-19",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363168"
    },
    {
      "nct_id": "NCT06906055",
      "title": "Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Arterial Disease Below the Knee",
        "Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization"
      ],
      "interventions": [
        {
          "name": "Multicath",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Summa Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-04-03",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 2,
      "location_summary": "Wilmington, Delaware • Vineland, New Jersey",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Vineland",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06906055"
    },
    {
      "nct_id": "NCT01257750",
      "title": "Treatment of Corneal Neovascularization With Topical Pazopanib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Pazopanib (5mg/ml)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reza Dana, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-11",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257750"
    },
    {
      "nct_id": "NCT04620109",
      "title": "Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "KDR2-2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2020-08-26",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04620109"
    },
    {
      "nct_id": "NCT01402544",
      "title": "Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01402544"
    },
    {
      "nct_id": "NCT00100009",
      "title": "Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "TAC-PF",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-12-09",
      "completion_date": "2006-12-20",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100009"
    },
    {
      "nct_id": "NCT02543229",
      "title": "Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Macular Degeneration",
        "Retinal Diseases",
        "Retinal Degeneration",
        "Neovascularization, Pathologic"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "DRUG"
        },
        {
          "name": "Lucentis™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2015-07",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543229"
    },
    {
      "nct_id": "NCT00088192",
      "title": "Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "pegaptanib sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyetech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-08-30",
      "last_synced_at": "2026-10-26T22:57:45.373Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088192"
    }
  ]
}